No added value for a drug's new indication? Price should adjust, researchers say
As more follow-on treatments with incremental improvements win approval in the US and Europe, new research published yesterday notes that fewer than half of the first indication approvals for new drugs in the US and Europe were rated as having high therapeutic value.
Therapeutic value was determined in the study by ratings for first and supplemental indications made by France’s Ministry of Health and Germany’s Federal Joint Committee, based on evaluations and re-evaluations of drugs conducted and published as of December 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.